Russian scientists have discovered a new mechanism of action for the anti-influenza drug "Triazavirin" and have proposed a modification that enhances its effectiveness, which has begun to be tested in pre-clinical trials.
Hot Topics
The human body ages in leaps and bounds Scientists identify two critical ages
From your phone screen to your data How do malicious apps sneak in and steal your secrets?
Best Top Supplements for Improve Women Uterine Health
Triazavirin is used to treat influenza and other respiratory infections. Scientists have discovered that the active ingredient specifically targets hemagglutinin, a protein the virus uses to enter human cells. They have also found a way to modify the drug molecule to enhance its effectiveness. The modified version is currently undergoing preclinical trials.
Oleg Batyshev, the institute's deputy director for scientific affairs, says: "We have shown that the drug is capable of targeting another viral protein, against which its effect has not been previously reported. Based on this, we proposed modifying the existing drug. The surface protein hemagglutinin, which the influenza virus uses to enter cells, contains a special fusion peptide, which it releases like a harpoon, penetrating the cell membrane. Triazavirin can block this 'harpoon,' keeping it in its original state. If a small tail is added to its molecule, the fused peptide binds more strongly."
According to him, this modification reduces the chances of the virus entering the cell compared to the original drug. The effect of this substance was confirmed in experiments conducted on a human cell membrane model. Further trials—first on animals and then on humans—will take about five years.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media